Washington – Food and Drug Administration Commissioner Lester Crawford announced his resignation Friday, just two months after he was confirmed for the job.
His e-mail notice to the FDA staff gave no reason for his surprise decision to step down.
Sources familiar with his departure said Crawford was asked to resign, though it was unclear why.
Crawford has had a stormy tenure at the agency, which has been beset by criticism from both left and right over its actions regarding drug safety and emergency contraception.
He was also accused before his confirmation of having an improper relationship with a female colleague – a charge that independent investigators said both parties denied. The final report did note, however, some significant discrepancies between Crawford’s testimony and that of others in the commissioner’s office.
Within an hour of the resignation, the White House announced that President Bush had asked National Cancer Institute Director Andrew Von Eschenbach to serve as acting agency commissioner and said he would take over the agency immediately.
Crawford, an affable Georgian who has worked at the agency on four separate occasions over 30 years, explained his departure Friday by saying, “After 3 1/2 years as deputy commissioner, acting commissioner and, finally, as commissioner, it is time, at the age of 67, to step aside.”
Crawford is the second high-ranking administration official to resign in the past two weeks.
Federal Emergency Preparedness Agency Director Michael Brown resigned under pressure because of the agency’s performance during and after Hurricane Katrina.
Under Crawford’s leadership, the agency has been accused of being lax in its safety requirements after the discovery a year ago that the popular arthritis painkiller Vioxx increased the risk of heart attacks and strokes. The agency also has been buffeted by abortion politics over a proposal to make emergency contraception more easily available.
Crawford announced last month that the agency had delayed, once again, its decision on whether the “morning-after pill” Plan B would be available without a prescription.
An agency expert advisory panel overwhelmingly recommended in 2003 that the application be approved, but the agency on three occasions said the proposal was either unacceptable or incomplete.
Sens. Hillary Rodham Clinton, D-N.Y., and Patty Murray, D-Wash., complained that Crawford’s latest Plan B decision broke a promise made to them that the issue would be resolved by Sept. 1.
Clinton and Murray on Friday welcomed Crawford’s departure.
“With the resignation of Dr. Crawford, the FDA has a real opportunity to restore its battered reputation and nominate a leader with vision and drive to ensure that the FDA upholds its gold standard of drug regulation,” Clinton said.
